

ASX ANNOUNCEMENT

21 July 2023

EBR Systems to Present at 17th Bioshares Biotech Summit

Sunnyvale, California; 21 July 2023: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce that Senior VP of Business Development, Andrew Shute, will be presenting at the 17th Bioshares Biotech Summit in Hobart, Tasmania on 24 July 2023.

A copy of the presentation is attached below.

ENDS

This announcement has been authorised for release by the EBR Systems General Disclosure Committee, a committee of the Board of Directors.

For more information, please contact:

Company

Frank Hettmann
Chief Financial Officer
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems’ WiSE Technology

EBR Systems’ WiSE technology is the world’s only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart’s left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart’s left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements


This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company’s control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



Bioshares Conference Presentation

July 2023

Traditional pacemakers are suboptimal

Traditional pacemakers use wires or leads to deliver energy to the heart, which can lead to many problems




Coronary Sinus limits
Left Ventricle (LV) lead
placement locations



Pathway for
pathogens to
myocardium



Associated with
phrenic nerve
stimulation



Can migrate and
sometimes fracture



Difficult to place



LV lead must be
placed outside the
heart to avoid blood
clots

EBR has a wireless solution for heart failure patients

EBR's WiSE CRT System and other leadless pacemakers are complementary

WiSE CRT System fills the gap

Currently the only leadless solution globally for LV pacing including CRT.

Other wireless pacemakers are too big for LV pacing

This increases the risk of blood clots, restricting their use to right ventricle (RV) and right atrium (RA) pacing only.

Complementary solution

WiSE CRT System can be used in conjunction with wireless RV/RA pacemakers to deliver CRT.

Strong competitive protection

WiSE CRT System is protected by over 97 issued patents globally.

Left ventricle



EBR Systems
WiSE CRT System

Right ventricle/atrium




Medtronic
Micra®



Boston
Scientific
Empower®



Abbott
Aveir®




Dr. Jeffrey Alison, Monash Hospital, Melbourne.

Micra on the left, WiSE CRT device held by tweezers on the right.

Journey so far

Culmination of over a decade of planning, research and development



Pivotal SOLVE-CRT Study meets all endpoints

Positive results confirm WiSE CRT System as a highly effective treatment option for patients with heart failure

Primary efficacy endpoint met

-16.4%

$p = 0.003$

Decrease in in left ventricular end systolic volume
vs -9.3% target, showing improved heart function

Primary safety endpoint met

80.9%

$p < 0.001$

Patients free from type I complications **vs 70% target**



Success in high-risk patients

SOLVE-CRT patient pool consists of patients who have failed conventional CRT



Safety profile comparable to SoC

Other studies using standard of care (SoC) treatment for CRT upgrades have shown 81.3% freedom from device & procedure related complications¹



Other key data

All data analysed to date shows consistent, positive results in reversing heart failure symptoms and physiology



Other key data

Observed complication rates were higher in early phases and decreased with experience

Clear regulatory pathway

EBR's track record of successful engagement underpins confidence for FDA approval process

● 2019

FDA granted Breakthrough Device Designation to WiSE CRT System

Provides EBR with interactive and timely access to and input from the FDA during premarket development phase, and a prioritised review of regulatory submissions filed with the FDA.

● 2020

FDA approved trial re-design of pivotal study

Pivotal study was redesigned with the FDA to be completed with a single-arm, treatment only phase. This was underpinned by extensive clinical experience with >450¹ patients treated with WiSE CRT System to date.

● 2022

FDA approved leadless pacemakers as a co-implant in pivotal study

FDA approval to include leadless pacemakers as a co-implant in the pivotal SOLVE-CRT trial. If approved during the PMA submission, this would potentially expand EBR's addressable market by ~US\$550m.

● 2023+

Clear pathway to approval with modular submission approach

EBR has already submitted three out of five modules to the FDA. The fourth module is scheduled to be submitted by the end of 2023 and the final module by end of Q1 2024. EBR is targeting FDA approval by the end of Q4 2024.

On track to finalise PMA submission to the FDA by end of Q1 2024, with FDA approval expected by H2 2024

Focused commercialisation strategy

EBR will leverage its established partnerships and presence in the US to drive initial sales growth, targeting initial sales in H1 2025



Clinical trial sites to drive initial sales

- CRT market is concentrated - targeting high-volume CRT procedure sites
- 2025: Targeting US sites that have participated in the SOLVE-CRT trial and other high-volume sites with Key Opinion Leaders (KOLs)
- 2026-2027: Target top 200 to 250 clinical sites, representing >50% US CRT market



Specialist sales force established

- Execution of commercial launch supported by specialised direct sales force to target high volume sites
- SOLVE-CRT team in place with clinical and technical expertise of WiSE CRT device
- Grow from an initial 7 sales territories to 35 sales territories by the end of 2027

Strategy enhanced by market factors

EBR's commercialisation strategy is underpinned by 3 distinctive features



Unmet need & strong data

- Unmet need underscored by FDA Breakthrough Device designation
- Support of Key Opinion Leaders (KOLs)
- Low barrier to transition to become first-line therapy



Low hospital adoption barriers

- Low barrier for opening new accounts
- No capital equipment required and reimbursement available post-approval
- Proven and refined implanter training program



Reimbursement & High ASP

- New Technology Add-on Payment (NTAP) and Transitional Passthrough Payment (TPT) expected post FDA approval
- WiSE CRT System ASP:
 - US: US\$35,000¹
 - OUS: US\$20,000²

Note: ASP: Average Selling Price

¹ U.S. pricing with New Technology Add-on Payment (NTAP) post-approval

² Initial Phase "OUS Markets" limited to AU, UK, Germany, France, BeNSca

US\$2.6bn initial addressable market

At commercial launch, EBR estimates to have an initial addressable market of ~US\$2.6bn

Leadless Upgrades

- Patients with a leadless right ventricle pacemaker can only upgrade with WiSE CRT System to receive effective CRT
- WiSE CRT System used in conjunction with the Medtronic Micra (single chamber) or Abbott Aveir (single chamber) device



Chronic Lead Failure

Traditional CRT system implanted but has ceased to provide effective CRT

\$1.0bn

\$0.5bn

\$0.3bn

\$0.8bn

Acute Lead Failure

Unable to implant CRT wire in a new CRT patient

High Risk Upgrades

Patient requiring CRT, but is deemed too high risk for a conventional CS lead placement

Totally Leadless CRT is a growth market

The Totally Leadless CRT (TLC) market has the potential to grow by an additional US\$4.2bn

Upgrading dual chamber leadless

WiSE CRT System used in conjunction with the Abbott Aveir dual chamber device, received FDA approval July 2023



\$2.2bn segment TAM

Near term expansion opportunity (3-4 years)

TLC as first-line therapy

WiSE CRT System used in conjunction with any leadless device




\$2.0bn segment TAM

Near term expansion opportunity (~4 years)

Market expansion opportunity

The WiSE CRT System can be expanded for use in other patient groups, indications and geographies, increasing EBR's market opportunity and underpinning future growth



Upcoming milestones

EBR continues to achieve significant value catalysts and pave the way to future value creation

2023

- ✓ SOLVE-CRT 6 Month follow up completed for final patient in February 2023
- ✓ **Headline data released at Heart Rhythm Society conference**
- ✓ **Positive trial data unlocks second tranche of growth capital facility**
- ❑ Publication of manuscript in a peer reviewed medical journal
- ❑ Submit Clinical Module for PMA application to the FDA
- ❑ Present at industry conferences including APHRS¹

2024

- ❑ Submit Final PMA Module including transmitter upgrades
- ❑ Production of working rechargeable batteries for design verification testing
- ❑ Additional sub-studies published using SOLVE-CRT dataset
- ❑ Initiate ACCESS and TLC studies
- ❑ FDA approval in the US

2025+

- ❑ Commercial launch in the US
- ❑ Launch in select markets OUS² as reimbursement and regulatory coverage is secured
- ❑ Expand use of WiSE CRT System into new patient groups and geographies
- ❑ Launch of rechargeable battery

Investment highlights

EBR is focused on executing its clear and targeted commercialisation strategy to deliver shareholder value

High value market opportunity



Unique solution

No competition as the WiSE CRT system is complementary to other leadless devices



Large markets

Targeting initial addressable market of US\$2.6bn with expansion opportunity up to US\$9.6bn




Positive results

Safety and efficacy endpoints met for SOLVE-CRT trial and Breakthrough Device Designation granted



Focused strategy

Clear pathway to achieve FDA approval and progress commercialisation activities to achieve first sales



Strong team

Experienced management team with significant clinical development and commercial expertise

Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries ("EBR") current as at the date of this presentation. It should be read in conjunction with EBR's periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au.

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR's notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management's current expectations and beliefs. Such statements are typically identified by words such as 'may', 'could', 'believes', 'estimates', 'expects', 'anticipates', 'intends' and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results

may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR's management. EBR's results are reported under US GAAP. Certain financial data in this presentation is "non-IFRS financial information" under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR's CHES Depositary Interests ("CDIs") are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.

Appendix



Product development

EBR is developing a new rechargeable battery that will support WiSE CRT System in becoming a first-line therapy option and treat a broader suite of patients

Background

EBR is developing a rechargeable battery and wireless charging system based on feedback from implanters and patients

Benefits

- Reduces the need for future battery replacement surgery
- Recharge interval once per week¹
- 66% reduction in size from current battery

Development status

- Specifications and initial design completed
- First working product for testing expected in H1 2024
- Regulatory and commercial timing to be announced as project progresses



EBR's new rechargeable battery charges uses a patch and external device to provide non-invasive, wireless charging

Patient success story - Richard

EBR has allowed the patient to once again partake in all the activities he enjoyed before his heart failure

Pre heart failure

US Marine and Vietnam war veteran who enjoyed a very active and outgoing lifestyle

"Sport was a very big part of my life. I was an active person."



Onset of heart failure

Heart failure materially impact the patient's quality of life

- **2014:** Pacemaker implanted due collapsing from a low heart rate.
- **2016:** Developed pacing induced heart failure. Conventional lead-based CRT implanted. Multiple lead failures.
- **2017:** Rapid deterioration: *"I couldn't walk up a flight of stairs. I couldn't work, I couldn't do anything. I was just existing."*


Post WiSE CRT Implant

Post WiSE CRT implant, the patient has been able to enjoy everything he used to do

"I was energised immediately. I could now take out the bins and walk up a flight of stairs."

"I was able to resume daily walks and open water swimming. Got stronger and lost 20kg."

"I'm happy, extremely happy. It's given me my life back!"



Patient success story - Brian

The WiSE CRT device has helped the patient regain the ability to participate in his favourite activities

Pre heart failure

Scout leader and avid football fan who enjoyed outdoor activities

Brian enjoyed being outdoors, taking part in activities such as mowing the lawn or walking his dog. He is also an active AFL supporter and his ability to attend Melbourne FC games was hampered by progressive heart failure symptoms.



Onset of heart failure

Heart failure materially impact the patient's quality of life

- **2009:** Brian collapsed with heart block and was inserted with a pacemaker, 5 months later he required an upgrade to an ICD
- **Post pacemaker and ICD:** Brian developed shortness of breath and reduced exercise tolerance over several years, even whilst lying flat in bed
- He experienced difficulty with daily activities

"I thought if I wanted to live longer then getting the WiSE CRT implant had to be done. That's it!"

Post WiSE CRT Implant

Post WiSE CRT implant, the patient has been able to enjoy everything he used to do

"9 months post WiSE implant and I am able to wash the cars readily and can now mow the lawns. I even went to the AFL game and could walk up multiple flights of stairs. I haven't been able to do that for years!"

"I would definitely recommend other patients consider the WiSE device if they were in a similar situation."





Contact Us

Company

Andrew Shute
Sr. VP Global Business Development
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com